GLOBAL-AI-SUMMIT
22.10.2020 21:13:13 CEST | Business Wire | Press release
Saudi Arabia, represented by the Saudi Data and AI Authority (SDAIA), and the International Telecommunication Union (ITU) today announced a memorandum of understanding (MoU) to collaborate on initiatives aimed at supporting and strengthening efforts to optimize the benefits of AI technologies and applications for sustainable development.
Under the partnership, Saudi Arabia will support ITU in developing projects, activities and initiatives that will, among other things, aim to facilitate greater multi-stakeholder participation, international cooperation, and knowledge sharing to accelerate progress towards the UN Sustainable Development Goals (SDGs). This could potentially include developing initiatives such as an “AI Readiness Landscape Framework” that would explore and highlight country responses, progress and best practices related to AI policy frameworks.
The MoU was announced by HE Dr. Abdullah Bin Sharaf Alghamdi, President of SDAIA, and HE Houlin Zhao, Secretary-General of ITU, in a virtual ceremony as part of the Global AI Summit 2020.
“Around the world, nations have recognized the transformative potential of artificial intelligence and are preparing themselves to harness the benefit of AI to support their development strategies and goals,” said HE Dr. Abdullah Bin Sharaf Alghamdi.
“With the announcement of this MoU, Saudi Arabia intends to support ITU to design activities that will help strengthen global efforts to use AI technologies for the advancement of sustainable development and growth. SDAIA has been established to drive AI programs in the Kingdom, and enable Saudi Arabia to become a global leader in AI. Through this partnership we will support the sharing of knowledge and experience among all nations, to further the use of AI for the benefit of humanity,” HE Dr. Alghamdi said.
“AI is being used to tackle the world’s most pressing challenges, from climate change to the COVID-19 pandemic,” said ITU Secretary-General Houlin Zhao. “With only 10 years left to achieve the UN Sustainable Development Goals, ITU looks forward to working with SDAIA to develop projects and initiatives that can accelerate progress toward the SDGs and promote AI as a force for good ─ for humanity and the planet.”
Saudi Arabia is supporting ITU in this space as part of the Kingdom’s efforts to become a world leader in AI innovation and in advancing knowledge and research into the beneficial use of AI.
The Saudi Data and Artificial Intelligence Authority was founded in 2019 as a world-class governance body to drive Saudi Arabia’s AI programs and ecosystem, and to lead global innovation and enable economic development powered by AI.
SDAIA is hosting the Global AI Summit, an international forum that brings together some of the world’s leading decision makers, technologists, innovators and investors, under the theme of using AI for the good of humanity. The event explores the global disruption of the pandemic, and how the pandemic is changing and accelerating the transformative potential of AI and robotics to shape the new normal and create a better future for all.
About the Global AI Summit
The Global AI Summit, organized by the Saudi Data & AI Authority (SDAIA), is the world's premier platform for dialogue that brings together stakeholders from public sector, academia and private sector, including technology companies, investors, entrepreneurs and startups, to shape the future of Artificial Intelligence (AI).
https://www.theglobalaisummit.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022006102/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom